Amicogen, Inc. (KOSDAQ:092040)
2,570.00
+55.00 (2.19%)
At close: Dec 5, 2025
Amicogen Revenue
Amicogen had revenue of 10.14B KRW in the quarter ending September 30, 2025, a decrease of -74.58%. This brings the company's revenue in the last twelve months to 87.97B, down -43.52% year-over-year. In the year 2024, Amicogen had annual revenue of 173.60B with 8.57% growth.
Revenue (ttm)
87.97B
Revenue Growth
-43.52%
P/S Ratio
1.62
Revenue / Employee
372.74M
Employees
236
Market Cap
142.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 173.60B | 13.70B | 8.57% |
| Dec 31, 2023 | 159.90B | 15.61B | 10.82% |
| Dec 31, 2022 | 144.30B | 19.41B | 15.55% |
| Dec 31, 2021 | 124.88B | 9.02B | 7.79% |
| Dec 31, 2020 | 115.86B | 675.18M | 0.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |